Acute ischemic stroke triggers massive neuronal death and sets off a severe neuroinflammatory cascade. Under physiological conditions, microglial efferocytosis rapidly eliminates apoptotic cells and cellular debris to limit tissue destruction. When this protective clearance mechanism fails, dying neurons undergo secondary necrosis, which worsens cerebral edema and accelerates neurological deterioration. Recent experimental discoveries demonstrate that extracellular cold-inducible RNA-binding protein acts as a critical pathological driver of post-ischemic clearance failure.

Understanding Microglial Efferocytosis in Cerebral Ischemia

Efferocytosis represents a specialized phagocytic program through which resident microglia recognize, engulf, and degrade dying brain cells. In healthy central nervous system physiology, this process prevents the spillover of cytotoxic intracellular contents into the surrounding parenchyma. During an ischemic stroke, prompt microglial clearance suppresses the release of destructive pro-inflammatory cytokines and promotes tissue remodeling. Efferocytic clearance relies heavily on specialized surface receptors, particularly the proto-oncogene tyrosine-protein kinase receptor MerTK. However, acute cerebral ischemia severely alters the local microenvironment, leading to substantial downregulation of MerTK on microglial surfaces. Consequently, impaired phagocytic clearance permits dying cells to accumulate rapidly within the ischemic penumbra. Unengulfed apoptotic corpses undergo secondary lysis, releasing hazardous intracellular components that perpetuate sterile inflammation and exacerbate secondary brain damage. Therefore, maintaining functional microglial clearance remains essential for limiting infarct expansion and preserving neurological function after acute ischemic insults.

The Deleterious Role of Extracellular CIRP

Cold-inducible RNA-binding protein normally resides in the cellular nucleus, where it stabilizes target transcripts during environmental stress. However, cerebral hypoxia and cellular damage trigger the rapid translocation and active secretion of this molecule into the extracellular space. Researchers have identified extracellular CIRP as a potent damage-associated molecular pattern released in high concentrations into the cerebrospinal fluid during stroke. In systemic inflammation and radiation injury, extracellular CIRP is already known to paralyze macrophage antimicrobial responses. In the brain, elevated levels of this inflammatory mediator directly disrupt microglial clearance programs. Experimental models of transient middle cerebral artery occlusion demonstrate that genetic deletion of CIRP substantially preserves phagocytic competence. Animals lacking CIRP exhibit markedly higher MerTK expression, significantly reduced infarct volumes, and enhanced neurological scores compared to wild-type controls. Hence, extracellular CIRP functions as a major upstream inhibitor of endogenous neuroprotective clearance mechanisms within the post-stroke microenvironment.

Dissecting the TLR4, miR-155, and MafB Signaling Pathway

The molecular cascade initiated by extracellular CIRP begins with its binding to microglial Toll-like receptor 4. This ligation activates downstream intracellular signaling cascades that strongly induce the expression of microRNA-155. As a key pro-inflammatory non-coding RNA, microRNA-155 directly targets and represses the transcription factor MAF bZIP transcription factor B, commonly known as MafB. Because MafB serves as an indispensable master regulator of MerTK transcription, its sudden repression leads to rapid downregulation of MerTK receptor synthesis. Furthermore, the suppression of MafB impairs downstream cytoskeletal remodeling machinery required for engulfing cellular targets. As a consequence, microglia lose their physical ability to extend phagocytic cups and internalize apoptotic neurons. By delineating the TLR4/miR-155/MafB pathway, scientists have mapped the precise transcriptional mechanism through which extracellular alarms silence resolution pathways. This cascade explains how early danger signals hijack cellular programs to transform protective microglia into dysfunctional bystanders during acute cerebral infarction.

Therapeutic Rescue with Small Peptide C23

To counteract the deleterious effects of extracellular CIRP, researchers investigated targeted pharmacological interventions using the synthetic small peptide C23. Structurally designed to bind competitively to extracellular CIRP, the C23 peptide effectively prevents the mediator from engaging Toll-like receptor 4 on the microglial surface. In preclinical stroke models, administration of C23 significantly attenuated the upregulation of microRNA-155 in ischemic brain tissue. By preventing microRNA-155 induction, the peptide preserved intracellular MafB levels and maintained robust MerTK receptor expression on microglia. Consequently, C23 treatment completely rescued microglial clearance capabilities, leading to efficient removal of dying neurons in the penumbral zone. Furthermore, treated animals exhibited substantial reductions in brain edema, lower overall neuroinflammation, and improved long-term neurobehavioral performance. These promising findings highlight competitive peptide inhibition as a viable strategy to neutralize damage-associated molecular patterns and restore innate protective mechanisms during acute stroke.

Clinical Implications for Stroke Management

Current clinical management for acute ischemic stroke centers primarily on rapid revascularization through intravenous thrombolysis and mechanical thrombectomy. Although these interventions restore cerebral perfusion, reperfusion itself often unleashes a second wave of inflammatory injury that impairs functional recovery. Interventions that promote microglial clearance without causing systemic immunosuppression represent an exciting translational frontier in neurotherapeutics. Neutralizing extracellular CIRP or enhancing the downstream MafB/MerTK axis provides a complementary neuroprotective strategy alongside reperfusion therapy. Additionally, measuring extracellular CIRP levels in blood or cerebrospinal fluid could serve as a valuable prognostic biomarker for assessing post-stroke neuroinflammation. As preclinical testing advances toward translational trials, targeting specific inflammatory pathways offers real promise for extending therapeutic time windows and improving neurological outcomes for stroke survivors worldwide.

Frequently Asked Questions

What is microglial efferocytosis and why is it vital in acute stroke?

Microglial efferocytosis is the biological process whereby brain-resident microglia identify, engulf, and remove apoptotic or dying neurons. In acute ischemic stroke, this clearance mechanism prevents dying cells from undergoing secondary necrosis. Consequently, timely clearance stops the leakage of toxic intracellular contents, suppresses damaging neuroinflammation, preserves salvageable penumbral tissue, and promotes overall neural repair and recovery.

How does extracellular CIRP disrupt the efferocytosis machinery?

Extracellular CIRP acts as a damage-associated molecular pattern that binds to microglial Toll-like receptor 4. This interaction induces microRNA-155, which directly represses the transcription factor MafB. Because MafB drives the synthesis of the essential phagocytic receptor MerTK and controls cytoskeletal remodeling, its inhibition causes severe receptor downregulation, thereby paralyzing the microglial ability to engulf apoptotic cells.

What therapeutic potential does the C23 peptide offer for stroke recovery?

The small synthetic peptide C23 competitively binds extracellular CIRP, preventing it from activating Toll-like receptor 4. By blocking this upstream trigger, C23 prevents microRNA-155 induction, preserves MafB transcription, restores MerTK expression, and rescues microglial clearance. In experimental models, C23 therapy significantly reduces brain infarction, curbs neuroinflammation, and improves long-term functional survival.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. It is not intended to replace professional medical judgement, diagnosis, or treatment. Always seek the advice of a physician or other qualified healthcare provider with any questions you may have regarding a medical condition. While we strive to provide accurate and up-to-date information, medical knowledge is constantly evolving, and new research may emerge that supersedes the information provided here. Refer to the latest local and national guidelines for clinical practice.

References

1. Lapin D et al. Extracellular CIRP Dysregulates Microglial Efferocytosis in Acute Ischemic Stroke via the TLR4/miR-155/MafB Axis. Adv Sci (Weinh). 2026 Aug 15. doi: 10.1002/advs.77053. PMID: 42603289.

2. Cai W, Dai X, Chen J, et al. STAT6/Arg1 promotes microglia/macrophage efferocytosis and inflammation resolution in stroke. JCI Insight. 2019;4(20):e131355.

3. Denorme F, Rustad JL, Portier I, et al. Platelet-derived extracellular CIRP promotes inflammatory thrombosis and organ injury. Blood. 2022;140(12):1378-1390.